NCT04739319

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,500

participants targeted

Target at P75+ for all trials

Timeline
176mo left

Started Feb 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress27%
Feb 2021Nov 2040

First Submitted

Initial submission to the registry

February 1, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

February 2, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 4, 2021

Completed
19.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2040

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2040

Last Updated

February 9, 2024

Status Verified

February 1, 2024

Enrollment Period

19.8 years

First QC Date

February 1, 2021

Last Update Submit

February 7, 2024

Conditions

Keywords

Age Related Macular DegenerationGeographic AtrophyDrusenMacular disease

Outcome Measures

Primary Outcomes (2)

  • Investigate the underlying aetiology of Age-Related Macular Degeneration

    The first aim of this project is to comprehensively investigate the underlying aetiology of AMD, characterise the AMD phenotype by understanding the differences between those with AMD and healthy individuals.

    Up to 20 years

  • Characterise the natural history of Age-Related Macular Degeneration and factors associated with its rate of progression.

    The second aim of this project is to characterise the natural history of AMD and factors associated with its rate of progression. These aims will be achieved by using performing imaging and functional assessment of the retina, characterisation of the genetic, systemic and environmental factors, and by obtaining patient-reported outcomes.

    Up to 20 years

Study Arms (1)

Age-Related Macular Degeneration

Participants with Age-Related Macular Degeneration

Other: N/A Observational study

Interventions

N/A Observational study

Age-Related Macular Degeneration

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People in Australia aged 18 years or older with AMD or healthy controls, willing and able to provide informed consent, and willing to accept the study requirements.

You may qualify if:

  • years of age or older; and
  • either AMD (defined as having at least a medium druse \>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants

You may not qualify if:

  • ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or
  • any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre for Eye Research Australia

East Melbourne, Victoria, 3002, Australia

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Blood, saliva, urine or tear samples will be obtained, on selected participants, to obtain genetic information and systematic markers.

MeSH Terms

Conditions

Macular DegenerationGeographic Atrophy

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 1, 2021

First Posted

February 4, 2021

Study Start

February 2, 2021

Primary Completion (Estimated)

November 1, 2040

Study Completion (Estimated)

November 1, 2040

Last Updated

February 9, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will share

All collected IPD at the discretion of the Principal Investigator in a de-identified format

Locations